T2	eligibility 241 264	women at increased risk
T3	location 355 362	England
T4	location 364 380	Northern Ireland
T5	location 386 391	Wales
T6	No-of-participants 397 400	928
T7	outcome-Measure 797 821	willingness to prescribe
T8	outcome-Measure 823 860	comfort discussing harms and benefits
T9	outcome-Measure 862 890	comfort managing the patient
T10	outcome-Measure 892 934	factors affecting the prescribing decision
T11	outcome-Measure 940 962	awareness of tamoxifen
T12	outcome 1069 1113	knew tamoxifen can reduce breast cancer risk
T1	intervention 103 117	GPs' attitudes
T14	control 703 744	secondary care clinician [SCC] prescriber
T17	outcome 1144 1173	aware of NICE guideline CG164
T18	intervention-value 1356 1361	68.9%
T19	control-value 1369 1374	84.6%
T13	outcome 1242 1272	willing to prescribe tamoxifen
T20	outcome 1414 1447	less comfort discussing tamoxifen
T21	intervention-value 1449 1454	53.4%
T22	control-value 1462 1467	62.5%
T15	intervention-value 1051 1056	51.7%
T16	control-value 1132 1137	24.1%
